At first, after the European Medicines Agency gave its approval in January, the AstraZeneca vaccine against COVID-19 was used for anyone who needed it in Germany. After discovering that especially younger people who had received the shot might face an increased risk of dangerous blood clots in the brain, however, on April 1, 2021, Germany's Standing Committee on Vaccination (Stiko) recommended not to use AstraZeneca to immunize people under 60 years old.
That meant quite a few people who had received their first dose of AstraZeneca had to then get BioNTech-Pfizer or Moderna for their second shot. Today, all adults in Germany, no matter their age, can be vaccinated with AstraZeneca again, if the patient and doctor have a conversation about the risks prior to the jab.
But a new study shows that combining two different vaccines might be more valuable than just an emergency solution. Researchers at Saarland University in western Germany have found that people whose first shot was AstraZeneca and whose second shot was BioNTech-Pfizer showed an immune response stronger than that in patients who had received two doses of the same vaccine.
So ? is it time to switch the world's immunization approach to a mix-and-match vaccination for everyone?
Not quite yet.
Preliminary results
The findings coming out of Saarland University are preliminary and have not yet been fully evaluated scientifically, the university emphasized in the press statement sharing the results. Before the researchers officially publish their findings, they will look into the role played by the age and gender of the patients, for example, and also delve deeper into which combinations can potentially trigger more severe side effects.
Even though a full data evaluation hasn't been completed yet, the team conducting the study was surprised by the clear results.
"That's why we wanted to share our outcomes now and not wait for the scientific evaluation process to be completed," Martina Sester, professor for transplantation- and infectional immunology at Saarland University, said in the press statement.
Ten times the antibodies
There were 250 people that participated in the trial conducted at the University Hospital in Homburg, Saarland, over the last few months. Some of them received two AstraZeneca shots, some received two BioNTech-Pfizer shots and a third group a combination of both.
The researchers compared the strength of participants' immune responses two weeks after the second shot. "We didn't just look at the number of antibodies against the coronavirus [the participants] developed, but also how effective the so-called neutralizing antibodies were," Sester explained. "That tells us how good the antibodies are at preventing the virus from entering our cells."
In terms of antibody development, the double-BioNTech as well as the combined AstraZeneca-BioNTech vaccination was significantly more effective than the double-AstraZeneca alternative. Participants who had one of the first two combinations of shots produced around 10 times more antibodies than those with two AstraZeneca jabs. And looking at the neutralizing antibodies, results with the mix-and-match vaccine approach were "even slightly better" than those achieved with two BioNTech shots, Sester said.
'Remarkable' boost in antibody production
The Spanish CombivacS trial, conducted with 663 participants at the Carlos III Health Institute in Madrid, came to a similar conclusion. The study's preliminary results were reported in the scientific journal Nature. Like the results from Saarland University, they are not yet final ? the publication in Nature is an overview of what the researchers in Spain have found so far, and not a full, peer-reviewed article.
Two-thirds of participants received a shot of the BioNTech-Pfizer vaccine after their initial AstraZeneca jab. The last third had not received a second shot at the time the initial results were shared. Magdalena Campins, an investigator on the CombivacS study at the Vall d’Hebron University Hospital in Barcelona, reported that those who had received the full mix-and-match vaccine combination began producing much higher levels of antibodies after their second shot, and these antibodies were able to recognize and inactivate SARS-CoV-2 in laboratory tests.
"It appears that the [BioNTech-]Pfizer vaccine boosted antibody responses remarkably in one-dose AstraZeneca vaccines," said Zhou Xing, an immunologist at McMaster University in Hamilton, Canada, that was not involved in the study, in the Nature article. Xing added that the boost appeared to be even more pronounced in people who had received their second dose of the AstraZeneca vaccine.
However, aside from the fact that its results aren't yet finalized and peer-reviewed, one problem with this study out of Spain is that it doesn't include a control group of people who received two shots of the same vaccine — so no direct comparison between the two groups was possible.
Vaccine combination 'should be seriously considered'
If the initial results are anything to go by, the combination of AstraZeneca and BioNTech-Pfizer appears to be a promising way to immunize people against COVID.
That's not because the two vaccines are in any way similar, though. They represent two types of COVID vaccines currently on the market.
The AstraZeneca shot is a traditional vector vaccine. It uses a harmless version of a different virus to deliver instructions to human cells, which learn to build up antibodies against the coronavirus.
The BioNTech jab is an mRNA vaccine, a new kind of immunization method. MRNA vaccines teach human cells how to make a protein that in turn triggers an immune response and the production of antibodies.
Researchers don't yet have enough information to know why the combination of these two vaccines can result in boosted immunity. Saarland University professor Sester said she was looking forward to seeing more research done on combining different types of vaccines and how they interact. "We believe that if other research teams reach conclusions similar to ours, the combination of vector- and mRNA vaccines should be seriously considered," she said. (UNI)
